The New England Journal of Medicine
Congratulations to Jeffrey Zonder, M.D., leader of the Multiple Myeloma and Amyloidosis Multidisciplinary Team at Karmanos Cancer Institute. Dr. Zonder co-authored a paper that was recently published by The New England Journal of Medicine. Titled “Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis,” the paper includes the results of a randomized trial, which led to the first FDA approval of any therapy for AL amyloidosis: Daratumumab-FasPro + CyBorD. Three former Karmanos fellows are also co-authors.
Click here to view the article.